34 results about "Coronaviridae" patented technology

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5′-terminal end 40 bases of the positive-sense RNA strand of the virus.

The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention.

Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpes viridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhoea virus), SARS (severe acute respiratory syndrome) causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

The invention belongs to the technical field of medicines, and relates to phosphoramidate derivatives of nucleoside compounds, uses of the phosphoramidate derivatives, and a pharmaceutical compositioncontaining the compounds. The derivatives and pharmaceutical composition can be used as an antiviral reagent, especially an anti-novel coronavirus (SARS-CoV-2) reagent. The invention also relates toa method for preparing the compounds and the pharmaceutical composition, and the use of the derivatives and pharmaceutical composition to prevention or treatment of viral infections, including but notlimited to, Flaviviridae viral infections, Filoviridae viral infections, Enteroviridae viral infections, Orthomyxoviridae viral infections, Paramyxoviridae viral infections, coronaviridae viral infections, particularly novel coronaviridae (SARS-CoV-2) infections.

The present invention discloses a strain of porcine epidemic diarrhea virus and a separation culture method. According to the present invention, the virus is Coronaviridae Coronavirus porcine epidemic diarrhea virus, is named PEDV/CH/BJ/2014, and has the preservation number of CGMCC No.10111; the culture of the virus requires a blank DMEM culture liquid containing trypsin; and the porcine epidemic diarrhea virus has good immunogenicity, is the current domestic epidemic variant, can be used for preparing PEDV diagnosis kit, PEDV attenuated vaccines and inactivated vaccines, and enriches the existing PEDV vaccine resources.

The invention discloses a COVID-19 data acquisition and analysis system, and belongs to the field of data acquisition and analysis. The system provides service and assistance for medical staff and government decision makers and provides important support for scientific research of novel coronavirus by fully utilizing various information including treatment schemes, medication data, inspection data, test data, image data, epidemiological data and the like. The system is constructed according to the characteristics of the COVID-19 novel coronavirus pneumonia, has strong specialty, connects epidemiological data with treatment schemes, inspection data, test data, medication data and image data of patients according to the identification numbers or identification numbers of the patients in thedata acquisition and analysis process, realizes the data fusion of public health data and internal information systems of hospitals, and is favorable for comprehensively knowing the COVID-19 novel coronavirus pneumonia.

The invention provides a nanoparticle based coronavirus vaccine. The vaccine includes nanoparticles, the nanoparticles include fusion protein, wherein the fusion protein includes at least one immunogenic part of S protein of viruses in coronaviridae and at least one part of a self-assembled monomer subunit connected to the at least one immunogenic part of the S protein; and the at least one immunogenic part of the S protein is shown on the surfaces of the nanoparticles. The coronavirus vaccine can be used for preventing and/or treating coronavirus infections.

The invention refers to the new use of HHV8 chemotactic factor vMIP and the ramification and other albumen factor in the pharmacy field, especially refers to the use in preventing and curing the SARScorresponding Coronaviridae infection. The invention uses vMIP-I, vMIP-II, vMIP-III of recombined HHV8, combines the process that the E albumen of SARS coronaviridae can resist the virus infecting the cell, the invention has prominent effect on decreasing the infection rate of SARS coronaviridae to kidney cell Vero E6, the mechanism is that the combination with homologous E albumen receiver prevents the infection, so it is possible that human control SARS disease effectively.

Provided is a method for treating a viral infection such as a viral infection caused by a coronaviridae virus, for example. Compositions having at least oleandrin are used in the treatment of viral infections.

A method of inhibiting or treating infection by Coronaviridae virus of a susceptible host is provided that includes the administration of immune anti-Coronaviridae secretory IgA having a recombinant secretory component to at least one of tissue of the susceptible host. The administration being prior to, or after the susceptible host is exposed to the Coronaviridae virus. A composition for such administration is also provided.

The invention provides an application of a recombinant cytokine gene-derived protein or a fragment thereof in inhibiting the activity of a coronaviridae virus. The recombinant cytokine gene-derived protein comprises an amino acid sequence SEQ ID NO: 1, or an amino acid sequence having at least 90% identity with the amino acid sequence SEQ ID NO: 1. In addition, the invention also provides application of the recombinant cytokine gene derived protein or the fragment thereof in preparation of drugs for preventing or treating diseases or symptoms related to coronaviridae viruses in subjects. The recombinant cytokine gene derived protein or fragment thereof according to the present invention has enhanced anti-coronaviridae virus activity compared to human interferon [alpha]2b (HuIFN-[alpha]2b).

Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses thereof are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may comprise a tapiviridae, a bunyaviridae, an arenaviridae, a coronaviridae, a flaviviridae, a picornaviridae, eastern equine encephalitis, western equine encephalitis, and Venezuela equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika viral infections.